|Email Newsletters from Pharmaceutical Technology and Pharmaceutical Technology Europe|
Providing the latest business, scientific, and regulatory news for the pharmaceutical and biotech industries.
News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts.
IFPMA Outlines Global Health Initiatives
The complexity of global health concerns requires the engagement of national and regional governments, the private sector, nongovernmental organizations, and other civil-society organizations. For the pharmaceutical industry, this involvement can be through individual companies and collective industry actions. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) is an important instrument of collective participation on global health concerns. IFPMA represents 26 multinational research-based pharmaceutical companies and 45 national industry associations in North America, Western Europe, Japan, Australia, Central and South America, Asia, and Africa. Eduardo Pisani, IFPMA’s director general, recently spoke with Pharmaceutical Technology to discuss the association’s policy objectives and action plans in global health, including influenza pandemic preparedness, noncommunicable diseases, counterfeit medicines, and neglected tropical diseases.
IFPMA’s framework of action
Pisani outlines IFPMA’s focus in drug quality, innovation, and access. “In the area of quality, IFPMA’s role is to advocate for policies and regulations aimed at ensuring that quality standards of medicines and vaccines are consistently implemented in all countries,” he explains, “and to provide expertise and capacity-building support so that patients’ health is not comprised by substandard or counterfeit medicines, particularly in developing countries.” In the area of innovation, Pisani says IFPMA’s aim is “to help create a global policy environment that is conducive to biopharmaceutical innovation for the benefit of all patients.” With regard to access to medicines, he emphasizes that the association “advocates policies and seeks partnerships that facilitate substantial access to medicines around the world. This involves working to ensure that medicines are available to patients worldwide but also underscores the need to upgrade healthcare infrastructure so that they are capable of absorbing new therapeutic options.”
These three core areas of quality, innovation, and access serve as the framework for the specific work of IFPMA in global health, which increasingly requires partnerships between the private and public sector. “Nowadays, most of the work accomplished in the global public health arena is collaborative in nature, so multistakeholder partnerships are encouraged,” says Pisani, pointing to partnerships in research and development (R&D), capacity-building, training, or technology transfer.
He points to the collaborative focus inherent in the UN Millennium Development Goals (MDGs), a set of eight time-bound targets for addressing extreme poverty, hunger and disease (i.e., maternal and children's health and specific diseases, such as HIV/AIDs, malaria, and tuberculosis), gender equality, education, and environmental sustainability, particularly MDG Goal 8, which emphasizes global partnerships. “MDG Goal 8 specifically mentions the need for cooperation with pharmaceutical companies in the development of a global partnership to provide access to affordable, essential drugs in developing countries,” says Pisani. To illustrate IFPMA’s role in the MDGs, Pisani noted that IFPMA member companies have approximately 210 projects in place, worth an estimated $9.2 billion that address the health-related MDGs. By 2015, the date set for the MDGs to be realized, if the present trend is maintained, the value of these projects is expected to increase to $20 billion (excluding companies’ expenditures on R&D for diseases of the developing world), he adds.
Influenza pandemic preparedness
IFPMA supported the OEWG's plan, in particular for addressing key challenges, such as increasing the capacity of vaccine production and enabling access in developing countries. IFPMA also supports the WHO's financial parameters for the industry for the WHO Global Influenza Surveillance Network (GISN). GISN serves as a global alert mechanism for the emergence of influenza viruses with pandemic potential and is also the mechanism through which WHO recommends the content of the influenza vaccine for the subsequent influenza season.
The OEWG recommendation includes specific requirements for users of the GISN to ensure that vaccines and antivirals are made available to developing countries in the event of a future pandemic. During the most recent H1N1 pandemic, IFPMA vaccine manufacturers committed 166 million doses to meet the WHO target of 200 million vaccine doses for developing countries, according to IFPMA.
In commenting on the PIP framework, IFPMA recognized the importance of local production of vaccines and antivirals in pandemic preparedness and said it would continue to explore local production, pointing to investment made by member companies in several countries, including Mexico, Brazil, China, Indonesia, and Thailand. During the OEWG/PIP consultations, individual IFPMA members confirmed that they also were willing to voluntarily undertake a selection of actions in the event of a future pandemic, including production-capacity expansion and access to reverse-genetics technology, dependent upon skills, knowledge, financial management, public-health policy, and national regulation.
IFPMA supported the adoption of the OEWG/PIP recommendations by the World Health Assembly in May, but also pointed to the need to increase vaccine-production capacity. “It has reminded us that timely access to candidate vaccine viruses and reagents is vital; secondly, that rapid evaluation and approval mechanisms for vaccines must be in place along with effective distribution networks; and thirdly, that seasonal vaccination recommendations provide a means to reduce the burden of influenza whilst sustaining and increasing global vaccine production capacity,” said Pisani, in a May 24, 2011, IFPMA press release.
In an interview with Pharmaceutical Technology preceding the World Health Assembly meeting in May, Pisani noted the importance of participation of other stakeholders in global influenza pandemic preparedness. “We believe that national governments should play a crucial role in ensuring vaccines reach their population, including immunization policy of seasonal influenza as advised by WHO,” he said. “This would need to be accompanied by regulatory procedures, country surveillance, health-system surveillance, and rules for transfer of viruses to build on significant contributions to the global pandemic made by IFPMA members.”
To address the problem, the UN will hold a first-ever UN General Assembly High-Level meeting on noncommunicable diseases in New York in September 2011. IFPMA will be responsible for conveying the research-based pharmaceutical position on chronic diseases. “We believe that the experience in the developed world demonstrates the crucial role of changing risky behaviors and prevention,” says Pisani. “We also will be advocating for the effective, multistakeholder strategies at the global, regional, and national levels that are fully integrated into healthcare systems.” In this multistakeholder framework, he says that governments, the research-based pharmaceutical industry, civil society organizations, and health professionals can play a role in increasing education and awareness, improving early detection and disease surveillance, and facilitating implementation of prevention programs.
In April 2011, the first global Ministerial Conference on Healthy Lifestyles and Noncommunicable Disease Control was held in Moscow. Presented at that meeting was a survey conducted by IFPMA and the Association of International Pharmaceutical Manufacturers (AIPM), which is the Russian national pharmaceutical trade association. The survey, Population Attitude to Personal Health: Perception of Health, Understanding of Risk Factors, Morbidity and Mortality, which was conducted in Russia from January 2011 to April 2011, showed a significant gap between what people think their state of health is and the negative impact of their behavior, such as smoking, abuse of alcohol, obesity, and lack of physical exercise, has on their health. “The Russian study illustrates the scale of the challenge to be tackled not only in Russia, but in other countries, such as China and India,” says Pisani. He cites estimates that projects that between 2005 and 2015, China, India, and Russia could lose $200 billion to $550 billion in national income due to the effects of noncommunicable diseases.
At its meeting in May, the World Health Assembly discussed the report from the working group of Member States on Substandard/Spurious/Falsely-Labeled/Falsified/Counterfeit Medical Products on improving access to quality and affordable medical products. The assembly approved the decision to extend the working group to resume its work and report to the next World Health Assembly. In commenting on the action, IFPMA stressed the importance of continuing and strengthening the efforts against anticounterfeit drugs. “The decisions taken on fake medicines provide a viable basis to build on existing work,” said IFPMA in a May 24, 2011, release. “It remains, however, in the longer term vital to establish a platform for international collaboration to protect patients from the dangers of fake medicines.”
Neglected tropical diseases
Private-sector support through R&D and direct financial contributions are part of the solution to addressing the problem of neglected tropical diseases. “IFPMA has supported WHO’s efforts to ensure that neglected tropical diseases receive greater attention,” says Pisani. In its 2010 report, WHO identified the contributions made by the pharmaceutical industry. Some specific company initiatives include:
Aside from financial and product donations, Pisani points to collaborative R&D models that the industry is using to address neglected tropical diseases. He points to GlaxoSmithKline’s “open-innovation” strategy of sharing intellectual property in the area of neglected tropical disease. This approach was further advanced by the creation of a nonprofit organization, BIO Venture for Global Health, which provides scientists and their institutions with access to compounds, technologies, and expertise. Pfizer, along with the Drugs For Neglected Diseases initiative, have allowed affiliated institutes to screen approximately 150,000 compounds in Pfizer’s library for African sleeping sickness and Chagas disease. AstraZeneca partnered with the Medicines for Malaria Venture to permit 500,000 compounds in its library to be screened.
Using technology to improve healthcare delivery and access to medicines is another important component in global public health. Pisani points to the SMS for Life pilot, a public–private partnership initiated by Novartis with IBM, the mobile-telecommunications company Vodafone, and the Ministry of Health in Tanzania that uses mobile phones, short-message service (SMS) messages, and electronic-mapping technology to monitor stock levels of artemisinin-based combination therapies and quinine injectables at health facilities on a weekly basis as a way to eliminate medicine stockouts for these malaria treatments. The pilot was conducted during a five-month period in September 2009 and covered 226 villages and more than 1 million people in Tanzania with strong results. For example, during the first eight weeks, in one district, the number of health facilities with stock-outs was reduced by more than 75%.
IFPMA also is joining with other stakeholders to support plans to combat antimicrobial resistance, which was the theme of WHO’s World Health Day this year. “While recognizing the R&D-based pharmaceutical industry’s role in innovation, we called for viable approaches, including incentives, and support from other stakeholders in creating an environment that ensures new antibiotics continue to be developed.